|  Help  |  About  |  Contact Us

Publication : Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

First Author  Kwak EL Year  2006
Journal  Cancer Res Volume  66
Issue  4 Pages  1923-8
PubMed ID  16488990 Mgi Jnum  J:106663
Mgi Id  MGI:3619183 Doi  10.1158/0008-5472.CAN-05-1237
Citation  Kwak EL, et al. (2006) Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 66(4):1923-8
abstractText  A truncating allele of the cell cycle checkpoint kinase CHK2 is present in 1% of the population, conferring a moderate increase in breast cancer risk, and inactivation of chk2 enhances mammary tumorigenesis in mice with targeted inactivation of brca1. We used the mouse mammary tumor virus (MMTV) promoter to target expression of a kinase-dead CHK2 allele (D347A). Mammary tumors, of predominantly micropapillary histology, developed in 40% of MMTV-CHK2-D347A transgenic mice with an average latency of 20 months. Tumors metastasized to lung and spleen; tumor-derived cell lines were frequently aneuploid and showed suppression of irradiation-induced p53 function. Primary hematopoietic malignancies were also observed in the spleen, another site of MMTV expression. The increased rate of tumor formation in MMTV-CHK2-D347A mice, compared with the relatively low incidence in chk2-null mice, provides a model to study modifiers of CHK2-dependent transformation.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

Trail: Publication

0 Expression